Coherus Oncology (CHRS) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Invivyd (IVVD) over the past year, losing 39.2% versus a loss of 57.3%. Over five years, CHRS leads with a -93.7% price change compared with -97.8% for IVVD. Invivyd is the larger company by market cap ($209.6 million vs $168.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | IVVD |
|---|---|---|
| Share price | $1.09 | $0.7111 |
| Market cap | $168.42M | $209.60M |
| 1-day change | +1.88% | +1.53% |
| YTD return | -24.65% | -71.64% |
| 1-year return | -39.20% | -57.29% |
| 5-year return | -93.71% | -97.84% |
| EPS (TTM) | $-1.25 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $3.07 |
| 52-week low | $0.974 | $0.528 |
| Distance from 52-week high | -58.33% | -76.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +610.94% | +1306.27% |
| Average volume | 1.16M | 4.90M |
| Shares outstanding | 154.50M | 294.76M |
| Employees | 144 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CHRS has outperformed IVVD by 18.1 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
CHRS vs IVVD FAQ
Which is bigger, Coherus Oncology or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $209.60M compared with $168.42M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or IVVD?
CHRS returned -39.20% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.